If you have been reading about Carcinogenicity and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516, GW-501516, GW 501516, endurobol | Names vary in research and anti-doping documents. |
| Chemical class | Synthetic PPARδ agonist | Small-molecule nuclear receptor ligand. |
| CAS Registry Number | 317318-70-0 | Identifier commonly associated with GW501516. |
| Appearance | White to off-white powder | Typical for purified research material. |
| Solubility | Low in water; soluble in DMSO and ethanol | Organic solvents are common for laboratory stock solutions. |
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
== Heterocyclic amines and neurological disorders == Harmane, a β-carboline alkaloid found in meats is "highly tremorogenic" (tremor inducing). While harmane has been found in roughly 50% higher concentrations in patients with essential tremor than in controls, there is no direct correlation between blood-levels and levels of daily meat consumption, suggesting a difference in metabolism of this chemical plays a greater role. These chemicals are formed during the cooking process of meat, particularly the longer they are cooked, and the more they are exposed to high temperatures during cooking.
In 66 AD, the Roman tribune Neapolitanus met with King Agrippa II in Iamnia, to inform him of his mission to investigate the situation in Jerusalem, following Florus' seizure of Temple funds and clashes between Jews and Roman troops. Later, in spring 68 AD, after the Roman army under Vespasian quelled the insurrection in Galilee, the army marched upon Iamnia and Azotus, taking both towns and stationing garrisons within them. Following the failure of the revolt and the destruction of the Second Temple, Judaism underwent significant reform in Yavne. According to rabbinic tradition, Rabbi Yohanan ben Zakkai and his disciples were permitted to settle in Iamnia during the outbreak of the war, after ben Zakkai, realizing that Jerusalem was about to fall, departed the city and sought the permission of Vespasian, commander of the Roman forces, to settle in Yavne and teach his disciples. Upon the fall of Jerusalem, his school functioned as a Sanhedrin. It was also theorized for some time to have been the site of a supposed Council of Jamnia that established the rabbinic Jewish biblical canon (although current scholarship largely rejects the theory that such a council in fact occurred). According to the Jerusalem Talmud (Berakhot 1:4), when the rabbis argued over some fine point of Jewish law, a Divine voice (Hebrew: bat ḳol) was heard in Yavne, ruling in favor of the School of Hillel.
The hydroponic method of plant production by means of suspending the plant roots in a solution of nutrient-rich, oxygenated water. Traditional methods favor the use of plastic buckets and large containers with the plant contained in a net pot suspended from the centre of the lid and the roots suspended in the nutrient solution. The solution is oxygen saturated by an air pump combined with porous stones. With this method, the plants grow much faster because of the high amount of oxygen that the roots receive. The Kratky Method is similar to deep water culture, but uses a non-circulating water reservoir.
== Labeling == The actual leather content of bonded leather varies depending on the manufacturer and the quality level. There is some debate and controversy over the ethics of using the term "bonded leather" to describe an upholstery product, which is actually a reconstituted leather, specifically in the home furnishings industry. A Leather Research Laboratory commented calling a product "bonded leather" is "deceptive because it does not represent its true nature. It's a vinyl, or a polyurethane laminate or a composite, but it's not leather". In 2011 the European Committee for Standardization published EN 15987:2011 'Leather - Terminology - Key definitions for the leather trade' to stop confusion about bonded leather, according to which the minimum amount of 50% in weight of dry leather is needed to use the term "bonded leather". The US Federal Trade Commission recommends giving a percentage of leather included. The Federal Trade Commission has said that "The guidelines caution against misrepresentations about the leather content in products containing ground, reconstituted, or bonded leather, and state that such products, when they appear to be made of leather, should be accompanied by a disclosure as to the percentage of leather or other fiber content. The guidelines also state that these disclosures should be included in any product advertising that might otherwise mislead consumers as to the composition of the product."
==== MeSH D12.776.467.374.400 – growth substances ==== MeSH D12.776.467.374.400.442 – hematopoietic cell growth factors MeSH D12.776.467.374.400.442.240 – colony-stimulating factors MeSH D12.776.467.374.400.442.240.075 – colony-stimulating factors, recombinant MeSH D12.776.467.374.400.442.240.075.350 – granulocyte colony stimulating factor, recombinant MeSH D12.776.467.374.400.442.240.075.350.275 – filgrastim MeSH D12.776.467.374.400.442.240.075.375 – granulocyte macrophage colony-stimulating factors, recombinant MeSH D12.776.467.374.400.442.240.150 – erythropoietin MeSH D12.776.467.374.400.442.240.150.250 – erythropoietin, recombinant MeSH D12.776.467.374.400.442.240.150.250.250 – epoetin alfa MeSH D12.776.467.374.400.442.240.350 – granulocyte colony-stimulating factor MeSH D12.776.467.374.400.442.240.350.375 – granulocyte colony stimulating factor, recombinant MeSH D12.776.467.374.400.442.240.350.375.275 – filgrastim MeSH D12.776.467.374.400.442.240.375 – granulocyte-macrophage colony-stimulating factor MeSH D12.776.467.374.400.442.240.375.275 – granulocyte macrophage colony-stimulating factors, recombinant MeSH D12.776.467.374.400.442.240.400 – interleukin-3 MeSH D12.776.467.374.400.442.240.500 – macrophage colony-stimulating factor MeSH D12.776.467.374.400.442.240.750 – thrombopoietin MeSH D12.776.467.374.400.442.800 – stem cell factor MeSH D12.776.467.374.400.505 – interleukins MeSH D12.776.467.374.400.505.501 – interleukin-1 MeSH D12.776.467.374.400.505.502 – interleukin-2 MeSH D12.776.467.374.400.505.503 – interleukin-3 MeSH D12.776.467.374.400.505.504 – interleukin-4 MeSH D12.776.467.374.400.505.505 – interleukin-5 MeSH D12.776.467.374.400.505.506 – interleukin-6 MeSH D12.776.467.374.400.505.507 – interleukin-7 MeSH D12.776.467.374.400.505.508 – interleukin-8 MeSH D12.776.467.374.400.505.509 – interleukin-9 MeSH D12.776.467.374.400.505.510 – interleukin-10 MeSH D12.776.467.374.400.505.511 – interleukin-11 MeSH D12.776.467.374.400.505.512 – interleukin-12 MeSH D12.776.467.374.400.505.513 – interleukin-13 MeSH D12.776.467.374.400.505.514 – interleukin-14 MeSH D12.776.467.374.400.505.515 – interleukin-15 MeSH D12.776.467.374.400.505.516 – interleukin-16 MeSH D12.776.467.374.400.505.517 – interleukin-17 MeSH D12.776.467.374.400.505.518 – interleukin-18 MeSH D12.776.467.374.400.800 – transforming growth factor beta
Sources: en.wikipedia.org
Yohimbine selectively blocks the pre-synaptic α2-adrenergic receptors. Blockade of post-synaptic α2-adrenergic receptors causes only minor corpus cavernosum smooth muscle relaxation, due to the fact that the majority of adrenoceptors in the corpus cavernosum are of the α1 type. Blockade of pre-synaptic α2-adrenergic receptors facilitates the release of several neurotransmitters in the central and peripheral nervous system—thus in the corpus cavernosum—such as nitric oxide and norepinephrine. Whereas nitric oxide released in the corpus cavernosum is the major vasodilator contributing to the erectile process, norepinephrine is the major vasoconstrictor through stimulation of α1-adrenergic receptors on the corpus cavernosum smooth muscle. Under physiologic conditions, however, nitric oxide attenuates norepinephrine vasoconstriction. Yohimbine binds to the a2 adrenergic receptor at a ratio of 40:1 and is the only a2 adrenergic receptor antagonist with no imidazoline receptor activity.
== Nomenclature == This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 2-dehydro-3-deoxy-D-gluconate:NAD+ 5-oxidoreductase. Other names in common use include 2-keto-3-deoxygluconate 5-dehydrogenase, 2-keto-3-deoxy-D-gluconate dehydrogenase, 2-keto-3-deoxygluconate (nicotinamide adenine dinucleotide, (phosphate)) dehydrogenase, 2-keto-3-deoxy-D-gluconate (3-deoxy-D-glycero-2,5-hexodiulosonic, and acid) dehydrogenase.
The process for class 1 inteins begins with an N-O or N-S shift when the side chain of the first residue (a serine, threonine, or cysteine) of the intein portion of the precursor protein nucleophilically attacks the peptide bond of the residue immediately upstream (that is, the final residue of the N-extein) to form a linear ester (or thioester) intermediate. A transesterification occurs when the side chain of the first residue of the C-extein attacks the newly formed (thio)ester to free the N-terminal end of the intein. This forms a branched intermediate in which the N-extein and C-extein are attached, albeit not through a peptide bond. The last residue of the intein is always an asparagine (Asn), and the amide nitrogen atom of this side chain cleaves apart the peptide bond between the intein and the C-extein, resulting in a free intein segment with a terminal cyclic imide. Finally, the free amino group of the C-extein now attacks the (thio)ester linking the N- and C-exteins together. An O-N or S-N shift produces a peptide bond and the functional, ligated protein. Class 2 inteins have no nucleophilic first side chain, only an alanine. Instead, the reaction starts directly with a nucleophilic displacement, with the first residue of the C-extein attacking the peptide carboxyl on the final residue of the N-extein. The rest proceeds as usual, starting with Asn turning into a cyclic imide. Class 3 inteins have no nucleophilic first side chain, only an alanine, yet they have an internal noncontiguous "WCT" motif.
=== Cancer === Ang has a prominent role in the pathology of cancer due to its functions in angiogenesis and cell survival. Since Ang possesses angiogenic activity, it makes Ang a possible candidate in therapeutic treatments of cancer. Studies of Ang and tumor relationships provide evidence for a connection between the two. The translocation of Ang to the nucleus causes an upregulation of transcriptional rRNA, while knockdown strains of Ang cause downregulation. The presence of Ang inhibitors that block translocation resulted in a decrease of tumor growth and overall angiogenesis. HeLa cells translocate Ang to the nucleus independent of cell density. In human umbilical vein endothelial cells (HUVECs), translocation of Ang to the nucleus stops after cells reach a specific density, while in HeLa cells translocation continued past that point. Inhibition of Ang affects the ability of HeLa cells to proliferate, which proposes an effective target for possible therapies.
Sources: en.wikipedia.org
This process is referred to as acclimatization: the maximum rate of sweating increases and its solute composition decreases. The volume of water lost in sweat daily is highly variable, ranging from 100 to 8,000 millilitres per day (0.041 to 3.259 imp fl oz/ks). The solute loss can be as much as 350 mmol/d (or 90 mmol/d acclimatised) of sodium under the most extreme conditions. During average intensity exercise, sweat losses can average up to 2 litres (0.44 imp gal; 0.53 US gal) of water/hour. In a cool climate and in the absence of exercise, sodium loss can be very low (less than 5 mmol/d). Sodium concentration in sweat is 30–65 mmol/L, depending on the degree of acclimatisation. Horses have a thick, waterproofed, hairy coat that would normally block the rapid translocation of sweat water from the skin to the surface of the hair required for evaporative cooling. To solve this, horses have evolved a detergent-like protein, latherin, that they release at high concentrations in their sweat. Their perspiration unlike humans is created by apocrine glands. This protein, by wetting the horses' coat hairs facilitate water flow for cooling evaporation. The presence of this protein can be seen in the lathering that often occurs on the coats of sweating horses, especially when rubbed. In hot conditions, horses during three hours of moderate-intensity exercise can lose 30 to 35 litres (6.6 to 7.7 imp gal; 7.9 to 9.2 US gal) of water and 100 grams (3.5 oz) of sodium, 198 grams (7.0 oz) of chloride and 45 grams (1.6 oz) of potassium.
Venom evolved just once among all Toxicofera about 170 million years ago, and then diversified into the huge venom diversity seen today. The original toxicoferan venom was a very simple set of proteins that were assembled in a pair of glands. Subsequently, this set of proteins evolved independently in the various lineages of toxicoferans, including Serpentes, Anguimorpha, and Iguania. Several snake lineages have since lost the ability to produce venom, often due to a change in diet or a change in predatory tactics. In addition to this, venom strength and composition has changed due to changes in the prey of certain snake species. For example, the venom of the marbled sea snake (Aipysurus eydouxii) became significantly less toxic after the diet of this species changed from fish to strictly fish eggs. The evolution of venom is thought to be responsible for the enormous expansion of snakes across the globe. The mechanism of evolution in most cases has been gene duplication in tissues unrelated to the venom. Pre-existing salivary proteins are the likely ancestors of most venom toxin genes. Expression of the new protein in the venom gland followed duplication. Then proceeded natural selection for adaptive traits following the birth-and-death model, where duplication is followed by functional diversification, resulting in the creation of structurally related proteins that have slightly different functions.
== Evolution == OATPs are present in many animals, including fruit flies, zebrafish, dogs, cows, rats, mice, monkeys and horses. OATPs are not present in bacteria, indicating their evolution from the animal kingdom. However homologs do not correlate well with the human OATPs and therefore it is likely that isoforms arose by gene duplication. OATPs have however been found in insects, suggesting that their evolution was early in the formation of the animal kingdom.
Sources: en.wikipedia.org
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.
No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.
Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.